NCT04416646

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma

Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma: Observational Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 100 (actual)
• Sponsor: Istituto Oncologico Veneto IRCCS · Academic / Other
• Sex: All
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of Cabozantinib in the treatment of patients with renal cell carcinoma.

Conditions

• Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Cabozantinib	The regimen will be a single oral dose administered daily on a continuous schedule, taken with or without food. The standard dose is 60 mg per day, which can be reduced to 40 or 20 mg according to the latest version of the Summary of Product Characteristics-SPC available. The treating oncologist will evaluate the opportunity to prudentially start treatment at 40 mg/daily in patients screening positively at G8 screening tool, and then escalate to 60 mg/daily only in case of absence of toxicity ³grade 2 at subsequent cycles. Temporary suspensions of treatment are allowed according to the local practice and will be registered if ³ 7 days.

Timeline

• Start date: 2019-02-27
• Primary completion: 2023-06-26
• Completion: 2023-12-31
• First posted: 2020-06-04
• Last updated: 2026-04-13

Locations

1 site across 1 country: Italy